

www.fda.gov/CDERSBIALearn

A Deep Dive: GDUFA III Scientific Meetings May 15, 2023, 1:00 – 4:30 pm EDT		
Welcome (10 min)	Welcome and Overview - SBIA	1:00 - 1:10 pm
Opening Remarks (15 min)	Introduction to GDUFA III Meetings Lei Zhang, PhD Deputy Director, Office of Research and Standards (ORS) Office of Generic Drugs (OGD) Center for Drug Evaluation and Research (CDER)	1:10 - 1:25 pm
Talk 1 (25 min)	GDUFA III Redesigned Pre-Submission Meetings Karen Bengtson Supervisory Regulatory Health Project Manager, ORS OGD CDER	1:25 - 1:50 pm
Talk 2 (25 min)	GDUFA III Post-Complete Response Letter (Post-CRL) Scientific Meetings Tao Bai, PhD Senior Advisor, Office of Bioequivalence (OB) OGD CDER	1:50 - 2:15 pm
Break (15 min)	Break	2:15 - 2:30 pm
Admin (5 min)	Administrative Reminders - SBIA	2:30 - 2:35 pm
Talk 3 (25 min)	GDUFA III Product-Specific Guidance (PSG) Teleconferences Caliope Sarago, MHSA Senior Regulatory Health Project Manager, ORS OGD CDER	2:35 - 3:00 pm
Talk 4 (25 min)	GDUFA III Product-Specific Guidance (PSG) Meetings Hee Sun Chung, PhD Lead Pharmacologist, Division of Bioequivalence I (DB I) OB OGD CDER	3:00 - 3:25 pm
Q&A and Panel Discussion (60 min)	 Moderator: SBIA Staff <u>Panelists:</u> Speakers and: Rob Lionberger, PhD, Director, ORS OGD CDER Partha Roy, PhD, Director, OB OGD CDER Pinaki Desai, PhD, Senior Biologist, Office of Lifecycle Drug Products (OLDP) Office of Pharmaceutical Quality (OPQ) CDER John Ibrahim, PharmD, BCPS, Associate Director of Regulatory Affairs, Office for Regulatory Operations (ORO) OGD CDER David Coppersmith, JD, Division of Policy Development (DPD) Office of Generic Drug Policy (OGDP) OGD CDER 	3:25 - 4:25 pm
Closing Remarks (5 min)	Rob Lionberger, PhD, Director, ORS OGD CDER	4:25 - 4:30 pm